Recherche
Cancer du sein, Microenvironnement et Immunociblage : E. Liaudet-Coopman

Culié D, Viotti J, Modesto A, Schiappa R, Chamorey E, Dassonville O, Poissonnet G, Guelfucci B, Bizeau A, Vergez S, Dupret-Bories A, Garrel R, Fakhry N, Santini L, Lallemant B, Chambon G, Sudaka A, Peyrade F, Saada-Bouzid E, Benezery K, Jourdan-Soulier F, Chapel F, Ramay A, Roger P, Galissier T, Coste V, Ben Lakdar A, Guerlain J, Temam S, Mirghani H, Gorphe P, Bozec A Upfront surgery or definitive radiotherapy for patients with p16-negative oropharyngeal squamous cell carcinoma. A GETTEC multicentric study. Eur J Surg Oncol. 2021;47(2):367-374. doi:10.1016/j.ejso.2020.07.034

Rittore C, Méchin D, Sanchez E, Marinèche L, Ea V, Soler S, Vereecke M, Mallavialle A, Richard E, Duroux-Richard I, Apparailly F, Touitou I, Grandemange S TNFR1-d2 carrying the p.(Thr79Met) pathogenic variant is a potential novel actor of TNF?/TNFR1 signalling regulation in the pathophysiology of TRAPS. Sci Rep. 2021;11(1):4172. doi:10.1038/s41598-021-83539-9

Milliet F, Bozec A, Schiappa R, Viotti J, Modesto A, Dassonville O, Poissonnet G, Guelfucci B, Bizeau A, Vergez S, Dupret-Bories A, Garrel R, Fakhry N, Santini L, Lallemant B, Chambon G, Sudaka A, Peyrade F, Saada-Bouzid E, Benezery K, Jourdan-Soulier F, Chapel F, Sophie Ramay A, Roger P, Galissier T, Coste V, Ben Lakdar A, Guerlain J, Temam S, Mirghani H, Gorphe P, Chamorey E, Culié D Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study. Oral Oncol. 2021;112. doi:10.1016/j.oraloncology.2020.105041

Culié D, Lisan Q, Leroy C, Modesto A, Schiappa R, Chamorey E, Dassonville O, Poissonnet G, Guelfucci B, Bizeau A, Vergez S, Dupret-Bories A, Garrel R, Fakhry N, Santini L, Lallemant B, Chambon G, Sudaka A, Peyrade F, Saada-Bouzid E, Benezery K, Jourdan-Soulier F, Chapel F, Ramay A, Roger P, Galissier T, Coste V, Lakdar A, Temam S, Gorphe P, Guerlain J, Bozec A, Mirghani H Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric study. Eur J Cancer. 2021;143. doi:10.1016/j.ejca.2020.10.034

Boissière-Michot F, Chabab G, Mollevi C, Guiu S, Lopez-Crapez E, Ramos J, Bonnefoy N, Lafont V, Jacot W Clinicopathological Correlates of ?? T Cell Infiltration in Triple-Negative Breast Cancer. Cancers (Basel). 2021;13(4). doi:10.3390/cancers13040765

Chauvin M, Garambois V, Colombo P-E, Chentouf M, Gros L, Brouillet J-P, Robert B, Jarlier M, Dumas K, Martineau P, Navarro-Teulon I, Pépin D, Chardès T, Pèlegrin A Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells. Sci Rep. 2021;11(1):2231. doi:10.1038/s41598-021-81819-y

Ho-Pun-Cheung A, Bazin H, Boissière-Michot F, Mollevi C, Landas E, Bleuse J-P, Chardès T, Prost J-F, Pèlegrin A, Jacot W, Mathis G, Lopez-Crapez E Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples. Br J Cancer. 2020;122(3):397-404. doi:10.1038/s41416-019-0670-8

Seisen T, Mari A, Campi R, Peyronnet B, Bensalah K, Rioux-Leclercq N, Pfister C, Gobet F, Allory Y, Xylinas E, Neuzillet Y, Descotes J-L, Saada-Sebag G, Irani J, Delpech-Debiais C, Bigot P, Eymerit C, Crouzet S, Mege-Lechevallier F, Ruffion A, Decaussin-Petrucci M, Droupy S, Roger P, Durand X, Camparo P, Cussenot O, Rouprêt M Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review. Eur Urol Focus. 2020-10-23. doi:10.1016/j.euf.2020.10.004

Jacot W, Guiu S Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review. Cancers (Basel). 2020;12(4). doi:10.3390/cancers12040958

Corbeau I, Thezenas S, Colombo P-E, Jacot W Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Cancers (Basel). 2020;12(9). doi:10.3390/cancers12092666

Bourillon L, Demontoy S, Lenglet A, Zampieri A, Fraisse J, Jarlier M, Boissière-Michot F, Perrochia H, Rathat G, Garambois V, Bonnefoy N, Michaud H-A, Chardès T, Tosi D, Pèlegrin A, Azria D, Larbouret C, Bourgier C Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells. Int J Radiat Oncol Biol Phys. 2020;106(5):1039-1051. doi:10.1016/j.ijrobp.2019.12.020

Penault-Llorca F, Kwiatkowski F, Arnaud A, Levy C, Leheurteur M, Uwer L, Derbel O, Le Rol A, Jacquin J-P, Jouannaud C, Quenel-Tueux N, Girre V, Foa C, Guardiola E, Lortholary A, Catala S, Guiu S, Valent A, Boinon D, Delaloge S Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14). Breast. 2020;49. doi:10.1016/j.breast.2019.10.013

Mansouri H, Alcaraz L, Mollevi C, Mallavialle A, Jacot W, Boissière-Michot F, Simony-Lafontaine J, Laurent-Matha V, Roger P, Liaudet-Coopman E, Guiu S Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival. Cancers (Basel). 2020;12(5). doi:10.3390/cancers12051244

Jacot W, Mazel M, Mollevi C, D'Hondt V, Cayrefourcq L, Bourgier C, Berrabah F, Lopez-Crapez E, Bidard F-C, Viala M, Maudelonde T, Guiu S, Alix-Panabières C Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. Clin Chem. 2020;66(8):1093-1101. doi:10.1093/clinchem/hvaa121

Pirel M, Costes-Martineau V, Bauchet L, Fabbro M, Tourneret A, De Oliveira L, Durand L, Roger P, Gonzalez S, Cacheux V, Rigau V, Szablewski V Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas. Virchows Arch. 2020;476(6):891-902. doi:10.1007/s00428-019-02695-6

Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy P-J, Guiu S BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers (Basel). 2020;12(4). doi:10.3390/cancers12040828

Anastasi C, Rousselle P, Talantikite M, Tessier A, Cluzel C, Bachmann A, Mariano N, Dussoyer M, Alcaraz L, Fortin L, Aubert A, Delolme F, El Kholti N, Armengaud J, Fournié P, Auxenfans C, Valcourt U, Goff S-L, Moali C BMP-1 disrupts cell adhesion and enhances TGF-? activation through cleavage of the matricellular protein thrombospondin-1. Sci Signal. 2020;13(639). doi:10.1126/scisignal.aba3880

Lanotte R, Garambois V, Gaborit N, Larbouret C, Musnier A, Martineau P, Pèlegrin A, Chardès T Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking. Cancer Sci. 2020;111(7):2508-2525. doi:10.1111/cas.14458

Girard C, Lecacheur M, Ben Jouira R, Berestjuk I, Diazzi S, Mallavialle A, Larbret F, Gesson M, Schaub S, Pisano S, Audebert S, Mari B, Gaggioli C, Leucci E, Marine J-C, Deckert M, Tartare-Deckert S A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma. Cancer Res. 2020;80(10):1927-1941. doi:10.1158/0008-5472.CAN-19-2914

Larbouret C, Poul M-A, Chardès T [Mimicking polyclonal immune response in therapy: from combination of two monoclonal antibodies to oligoclonal antibody-based mixtures]. Med Sci (Paris). 2019;35(12):1083-1091. doi:10.1051/medsci/2019216

Darlix A, Hirtz C, Thezenas S, Maceski A, Gabelle A, Lopez-Crapez E, Firmin N, Guiu S, Jacot W, Lehmann S The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer. 2019;19(1):110. doi:10.1186/s12885-019-5287-z

Chartron E, Theillet C, Guiu S, Jacot W Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. Crit. Rev. Oncol. Hematol.. 2019;133. doi:10.1016/j.critrevonc.2018.10.012

Jacot W, Heudel P-E, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero J-M, Eymard J-C, Petit T, Mouret-Reynier M-A, Courtinard C, Cottu P, Robain M, Mailliez A Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Int J Cancer. 2019;145(12):3359-3369. doi:10.1002/ijc.32402

Le Clorennec C, Lazrek Y, Dubreuil O, Sampaio C, Larbouret C, Lanotte R, Poul M-A, Barret J-M, Prost J-F, Pèlegrin A, Chardès T ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell Commun Signal. 2019;17(1):106. doi:10.1186/s12964-019-0413-8

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés